Genetically engineered cell therapies with mRNA lipid nanoparticles for transferrable platelets

Platelet transfusions are essential in managing bleeding and hemostatic dysfunction, and can be expanded to be used as cell therapy for a variety of diseases. The efforts to create such cell therapies require that researchers modify donor platelets to express therapeutic proteins. However, at present, appropriate methods to genetically modify platelets collected from blood donors remain elusive.